Community Leukemia Clinical Research Drug Development
University of Colorado (CU) Cancer Center researchers have been on the leading edge of developing new therapies for leukemia. One of the most recent breakthrough therapies has been the development of venetoclax, a B-cell lymphoma-2 inhibitor, that that has shown profound results for adults with acute myeloid leukemia (AML) and has become a standard of care for patients with this disease all over the world.
Rachel Sauer | 
February 24, 2022
Cancer AstraZeneca Drug Development
AstraZeneca is pharmaceutical company committed to developing novel anti-cancer drugs. The University of Colorado Cancer Center is one of the fastest-growing academic cancer research centers in the United States, with hundreds of scientists and doctors working to better understand the disease. Recently, CU Cancer Center leaders visited the AstraZeneca Research and Development Campus in Gaithersburg, Maryland to discuss how a handshake between CU’s academia and AZ’s industry could help both take steps toward the ultimate goal: speeding the delivery of new drugs to cancer patients who need them.
Cancer Center | April 18, 2019
OncLive
August 24, 2023
In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.
Colorado Public Radio
August 15, 2023
Horse Barn Community Garden is in Five Points’ Curtis Park, near downtown Denver. This is where you’ll often find Charlotte Griffin, watering the vegetables.
Science News
August 14, 2023
Healio
August 08, 2023
A novel therapeutic approach that combined radiation and immunotherapy demonstrated the ability to eliminate pancreatic tumors and halt metastases.
